Relutrigine

DB21614InvestigationalSmall molecule

Relutrigine is a small molecule drug. The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator. Relutrigine is under... Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

Mechanism: Pharmacologically active on Sodium channel protein type 8 subunit alpha
Curator reviewed
Formula / weight: C₁₅H₁₁F₆N₅O₂ · 407.276 g/mol (avg)
Code names: PRAX-562

Resolves to

Compound

UNIIAW5C5XHM4WCAS2392951-29-8ChEMBLCHEMBL5314479

Structure

InChIKeyBFXBSYMVTNEFRF-UHFFFAOYSA-NSMILESCCOC(F)(F)C1=NN=C2C=NC(=CN12)C1=CC(F)=C(OCC(F)(F)F)N=C1

Targets

Q9UQD0SCN8A

What you can answer from here — as of September 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Relutrigine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account